MyOme
LightNews LightNews
banner
myome.com
MyOme
@myome.com
7 followers 7 following 6 posts
We help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies.
Posts Replies Media Videos
myome.com
Join us at #ACMG2025

We will be showcasing our upcoming rare disease products in our showcase, Advancing Rare Disease Diagnostics, on March 19th at 12:15 PM PST. Lunch will be provided. Register here: lnkd.in/gP847QVR
March 12, 2025 at 4:14 PM
Reposted by MyOme
dnanexus.bsky.social
Our next roundtable covers the challenges & strategies for integrating vast, multi-modal datasets into their clinical testing workflows. hello.dnanexus.com/webinar/inno...
@dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social h.bsky.social @myome.com
Live webinar: Innovations in Clinical Testing for Oncology & Rare Diseases. Taking place on march 6th at 11am ET.
February 25, 2025 at 5:28 PM
myome.com
Today we are excited to launch CAD iPRS — a cutting-edge, genome-wide polygenic risk score for coronary artery disease. Empowering primary care to identify high-risk patients and personalize prevention strategies.

Read more here: prnewswire.com/news-release...
February 27, 2025 at 4:38 PM
myome.com
MyOme’s Dr. Akash Kumar will speak at WashU Medicine’s Rare Disease Day event on:

📅 Feb 20 | 1:45PM PT / 3:45PM CT
🧬 Shortening Diagnostic Timelines for Rare Diseases – A Whole-Genome Platform Approach
February 19, 2025 at 6:38 PM
Reposted by MyOme
dnanexus.bsky.social
Join our discussion on clinical testing innovations that are enabling organizations to derive insights into #oncology & #raredisease. hello.dnanexus.com/webinar/inno...

@dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social @myome.com
Innovations in Clinical Testing for Oncology & Rare Diseases
Clinical testing for oncology and rare diseases faces unique challenges that demand innovative solutions. Patient recruitment and retention remain significant hurdles, with stringent eligibility crite...
hello.dnanexus.com
February 13, 2025 at 7:43 PM
myome.com
We're partnering with Novi Health to bring whole genome testing to employer health programs. Through this collaboration, employees and their families gain access to whole genome sequencing, integrated risk (with PRS) reports, and expert genetic counseling.
prn.to/4jzWF7T
MyOme and Novi Health Collaborate to Bring Whole Genome Testing to Employer Health Programs
/PRNewswire/ -- MyOme, a leading clinical innovation whole genomic analysis and polygenic risk modelling (PRS) company announced a strategic partnership with...
www.prnewswire.com
January 30, 2025 at 5:04 PM
myome.com
MyOme's CEO, Premal S. Shah, PhD, is excited to speak at #PMWC2025 on Feb 6 at 2 PM. We'll discuss integrated polygenic risk scores for breast cancer & coronary artery disease. Learn more: pmwcintl.com/program/ #PrecisionMedicine
January 14, 2025 at 5:49 PM
myome.com
Big news! 🧬 Natera & MyOme launch iPRS™, a personalized tool to assess breast cancer risk. Backed by research, iPRS integrates >1M genetic markers & clinical inputs for accurate, cross-ancestry insights.

Learn more: ow.ly/mGsJ50UntLt
#BreastCancer #Genetics
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testin...
ow.ly
December 9, 2024 at 5:38 PM